Arrowhead Pharmaceuticals Announces Inducement Grants for New Employees
Arrowhead Pharmaceuticals, Inc. reported the approval of restricted stock unit grants for 203 new employees as an inducement for their employment.
Stocks · News reference
Morgan Stanley analyst Michael Ulz has maintained an 'Overweight' (Buy) rating on Arrowhead Pharmaceuticals while lowering the price target from $120 to $106.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Arrowhead Pharmaceuticals, Inc. reported the approval of restricted stock unit grants for 203 new employees as an inducement for their employment.
Citigroup analyst Eric Joseph has reaffirmed a bullish rating and a $105 price target for Arrowhead Pharmaceuticals (ARWR).
Several major financial institutions updated their outlooks for Arrowhead Pharmaceuticals on November 14, 2026, with price targets ranging from $96 to $126.
Arrowhead Pharmaceuticals announced its financial results for the fiscal year ended September 30, 2026, and hosted a conference call to discuss the company's performance.
Arrowhead Pharmaceuticals, Inc. announced its scheduled participation in the 2026 Jefferies Global Healthcare Conference and Citi's 2026 Global Healthcare Conference.